# Foghorn Therapeutics Posts $0.80 Q3 GAAP EPS, $83.5 Million Revenue

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/52946
Published: 2026-11-10T09:05:31.000Z
Updated: 2026-11-10T09:05:31.000Z
Section: Business

> Research and development expenses fell $1.2 million from a year earlier.

Foghorn Therapeutics Inc. reported third-quarter GAAP earnings per share of $0.80 and revenue of $83.5 million, while research and development expenses declined from a year earlier.

The results cover the three months ended Sept. 30, 2026.

Research and development expenses totaled $18.8 million during the quarter.

That was $1.2 million below the $20 million recorded in the three months ended Sept. 30, 2025.